Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6-18 years with chronic hepatitis C-Results of the PANDAA-PED study.

Maria Pokorska-ŚpiewakEwa TalarekMałgorzata AniszewskaMagdalena PlutaAnna DobrzenieckaMagdalena MarczyńskaGiuseppe Indolfi

Published in: Liver international : official journal of the International Association for the Study of the Liver (2023)

Results of the PANDAA-PED study indicated a 100% effectiveness of a 12-week therapy with SOF/VEL in children aged 6-18 years with chronic HCV infection and its good safety profile, in particular in younger patients.

Keyphrases

liver fibrosis
end stage renal disease
ejection fraction
hepatitis c virus
randomized controlled trial
prognostic factors
peritoneal dialysis
stem cells
systematic review
young adults
bone marrow
human immunodeficiency virus
hiv infected